MEK inhibition and mTORC1, or mTORC1 and mTORC2 inhibition are synergistic in vitro and in vivo [13,84], and such a combination may be useful for PNs and MPNST treatment. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.